Thrombotic thrombocytopenic purpura in the presence of connective tissue disease and HIV infection: A diagnostic and therapeutic challenge in a resource- constrained setting by Perumal, Rubeshan et al.
IN PRACTICE
585       June 2016, Vol. 106, No. 6
Thrombotic thrombocytopenic purpura 
(TTP) is a multisystem disorder charac ter ised 
by microangiopathic haemolytic anaemia 
and resulting diffuse microcirculatory 
collapse. The classic clinical description is 
a pentad of thrombocytopenia, haemolytic 
anaemia, fever, renal dysfunction and 
neurological impairment. Acquired TTP 
accounts for the vast majority of clinical 
cases, and may be classic idiopathic TTP or 
secondary TTP. There has been a growing 
recognition of the secondary causes of TTP, 
which include, inter alia, collagen vascular 
disease, bone marrow transplantation, 
malignancy, pregnancy, infections and 
drugs. HIV-associated TTP has become a 
particularly important secondary cause of 
TTP in high-HIV-burdened settings. The 
association of TTP and connective tissue 
disease (CTD) was first described in 1961 
with a case of systemic lupus erythematosus 
complicated by TTP. Mixed CTD (MCTD), 
on the contrary, is rarely complicated by 
TTP, with only 14 cases being described 
in the literature to date. We describe the 
first case of TTP occurring in a patient 
with undifferentiated CTD and HIV 
infection, and the complexity of diagnosis 
and management in a resource-constrained 
setting. 
Case presentation
A 46-year-old black African woman was 
admitted with complaints of malaise, lethargy, 
fever, and headaches for a week. She was 
living with HIV, having been diagnosed in 
2010, with a baseline CD4 count of 109 cells/
µL. She was initiated on antiretroviral therapy 
(ART) within a month of her diagnosis and 
demonstrated a good response to therapy, 
with a suppressed viral load (VL) and a 
satisfactory rise in her CD4 count to 329 
cells/µL over 4 years. Two years prior to 
this admission, she had presented to the 
dermatology unit for investigation of a rash 
that she reported under both her breasts as 
well as over her abdomen. The presence of 
thickened plaque-like lesions was confirmed 
clinically. Histological examination revealed 
the lesions to be morphea, a form of localised 
scleroderma (Fig. 1).
On admission, she was ill-looking, pale, 
jaun diced and pyrexial (formal temperature 
of 38.3°C). The patient’s blood pressure was 
126/82, and her heart rate was 120 beats 
per minute. There was no Raynaud’s pheno-
menon, sausage fingers, arthritis or myositis. 
There were no cutaneous manifestations 
of systemic lupus erythema tosus (SLE) or 
features of systemic sclerosis. Examination 
of her respiratory system, cardiovascular 
system, nervous system and abdomen were 
normal. The full blood count revealed 
thrombocytopenia and normocytic normo-
chromic anaemia (Table 1). A review of 
the peripheral blood film confirmed true 
thrombocytopenia, marked fragmentation 
of red blood cells, the extensive presence 
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Fig. 1. Morphea or localised scleroderma.
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of schistocytes, polychromasia and nucleated red blood cells. The 
anti-nuclear antibody test was positive at a titre of 1:2 560, as was 
the anti-U1RNP antibody, and anti-Ro antibody. Other specific 
antibodies including anti-DNA, anti-Smith, anti-CCP, anti-Jo1, anti-
La, anti-Scl70, anti-centromere and antiphospholipid antibodies 
were negative. Raised lactate dehydrogenase and bilirubin levels, in 
the presence of a negative Coombs test, suggested the presence of 
non-autoimmune-mediated haemolytic anaemia. This was supported 
by a normal complement level. There was no evidence of sepsis or 
disseminated intravascular coagulopathy. Evaluation of iron studies, 
vitamin B12 and folate were normal. There was mild renal impairment 
with an estimated glomerular filtration rate of 58 mL/min/1.73 
m3. Urinalysis was normal, and a pregnancy test was negative. The 
CD4 count was 329 cells/µL, and the HIV VL was below detectable 
limits. The chest radiograph showed a normal cardiac shadow with 
normal lung fields. The clinical tapestry of thrombocytopenia, non-
autoimmune haemolytic anaemia, fever and renal dysfunction led 
to the consideration of TTP as the leading differential diagnosis. 
While a thorough systematic attempt was made to investigate for 
potential secondary causes of TTP, two important secondary causes 
were clinically and biologically plausible – CTD-associated TTP and 
HIV-associated TTP. A flare of her CTD was an initial concerning 
differential diagnosis, but this became less likely as the results of 
normal complement, and evidence that the haemolytic process was 
non-autoimmune mediated, became available. Our initial treatment 
strategy for TTP included prednisone 1 mg/ kg/ day, fresh dried 
human plasma (FDP) 30 mL/kg/day, red blood cell transfusion 
and gastric ulcer prophylaxis with omeprazole 20 mg daily. She was 
monitored closely for signs of clinical or haematological failure, 
and was recognised to have deteriorated neurologically with 
seizure activity on day 3 – completing the classic clinical pentad 
of TTP. Failure of the treatment strategy was further confirmed by 
persistent thrombocytopenia and ongoing haemolysis manifest by 
declining haemoglobin and rising lactate dehydrogenase (Fig. 2). 
Plasmapheresis was promptly added to the treatment strategy (day 3), 
but required transfer to another facility with access to this resource. 
An improving clinical and laboratory trend was seen after 5 days 
of daily plasmapheresis therapy using fresh dried human plasma 
(FDP) as the exchange fluid. After a week of treatment, platelet 
count and haemoglobin increased, and there was no evidence of 
ongoing haemolysis. 
Discussion 
Thrombotic thrombocytopenic purpura is an important disease 
entity to consider in any patient presenting with thrombocytopenia 
and evidence of haemolytic anaemia. With improved access to 
healthcare and more timely diagnosis, it is now less common to see 
the classically described pentad of thrombocytopenia, haemolytic 
anaemia, fever, neurological manifestations and renal dysfunction. [1] 
A more prudent diagnostic definition is that of microangiopathic 
haemolytic anaemia and thrombocytopenia, with or without renal 
failure or neurological abnormalities, and without another cause 
of thrombotic microangiopathy. The pathophysiology of TTP has 
become clearer with the discovery of ADAMTS13, a von Willebrand 
factor (VWF) cleavage enzyme. The central role of the protease, 
ADAMTS13, in the clinical expression of microcirculatory collapse 
has now been well established by laboratory studies that have 
demonstrated the propensity for microthrombosis in ADAMTS13 
deficiency.[2] VWF is a glycoprotein secreted by endothelial cells in 
response to endothelial injury, as large multimeric precursors referred 
to as unusually large VWF multimers (UL-VWFs). Without cleavage 
to smaller functional units, the UL-VWFs serve as potent surfaces for 
platelet aggregation and the bridging of platelets to the endothelium. 
It has therefore become apparent that the presence of an ADAMTS13 
deficiency and the resulting excess of circulating UL-VWFs leads 
to disseminated platelet-rich thrombi, which block terminal 
arterioles. Microangiopathic haemolytic anaemia results from the 
mechanical destruction of red blood cells as they pass through these 
arterioles. The diffuse presence of thrombi in the arterioles results 
in microcirculatory collapse, which finds expression in the eventual 
ischaemic compromise of the organ systems in which it occurs. The 
predilection for collapse of the cerebral and renal microcirculations 
Table 1. Initial laboratory findings
Test Result
Full blood count
White cell count (cells/L) 13.98 × 109
Haemoglobin (g/dL) 5.8 
Cell volume (fl), mean 93.1 
 Cell haemoglobin (pg), 
mean
30.1 
Platelet count (units/L) 8 × 109
Peripheral smear Thrombocytopenia
Marked fragmentation of red cells
Extensive schistocytes
Polychromasia
Nucleated red cells
LDH (U/L) 3 775 
Total bilirubin (µmol/L) 34 
Coombs (direct) Negative
International normalised ratio 1.0
PTT (s) 30 
Fibrinogen (g/L) 3.7 
Fibrin monomers Negative
Reticulocyte count, n 14.65
Corrected count, n 5.21
Reticulocyte production index 1.7
Blood cultures Negative
Urine cultures Negative
Sputum cultures (including 
tuberculosis)
Negative
ESR (mm/hr) >140 
CRP (mg/L) 44 
C3 (g/L) 1.76 
C4 (g/L) 0.31 
Anti-nuclear antibody Positive (titre 1:2 560, speckled 
pattern)
Anti-SSA(Ro) antibody Positive
Anti-URNP antibody Positive
Anti-DNA antibody Negative
Anti-Smith antibody Negative
Anti-SSB(La) antibody Negative
Anti-Jo1 antibody Negative
Anti-Scl70 antibody Negative
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is believed to be due to the high shear stress 
recorded in the vascular beds of these organs. 
However, the microcirculations of the heart, 
gastrointestinal tract and other organs have 
also been demonstrated to be potential sites 
of ischaemic compromise.[1] Congenital 
TTP due to an inherited deficiency in 
ADAMTS13 is exceedingly rare and seldom 
presents in adulthood. Idiopathic TTP is 
the most common form of TTP; it is an 
autoimmune disease characterised by the 
presence of auto-antibodies to ADAMTS13, 
which neutralise the cleavage enzyme and 
effectively result in reduced ADAMTS13 
activity. However, it is important to investigate 
for secondary causes of TTP before the 
disease can be deemed to be idiopathic 
or classic TTP. A list of these secondary 
causes includes HIV, pregnancy-related 
disorders, drugs, malignancy and CTDs. 
While the mechanisms by which they result 
in TTP differ, they take common expression 
in a consumptive thrombocytopenia and a 
microangiopathic haemolytic anaemia. In 
addition, measurement on ADAMTS13 has 
not been shown to be useful for clinical 
decision-making in routine practice. 
Severe ADAMTS13 deficiency may not 
conclusively confirm the diagnosis of TTP, 
as more probable alternative diagnoses have 
been shown to exist in the presence of low 
ADAMTS13 levels. 
There has been significant evolution in the 
treatments and outcomes for patients with 
TTP since the early 1900s. Corticosteroids, 
antiplatelet agents and splenectomy remained 
the primary methods of treatment until 
the mid-20th century, but resulted in the 
survival of only 10% of treated patients.[3] The 
subsequent discoveries of plasma infusion, 
plas ma pheresis (plasma exchange), and 
novel immune modulating therapies such as 
rituximab have resulted in a survival rate of 
nearly 90% in appropriately treated patients. [4] 
Plasma infusion replenishes ADAMTS13 
but does not remove ADAMTS13 antibodies 
from the patient’s blood. Plasmapheresis, too, 
is able to replenish ADAMTS13, but is also 
able to replenish normal VWF multimers, 
remove ADAMTS13 antibodies, and remove 
unusually large VWF multimers from the 
patient’s circulation.[5] While adjuvant steroid 
therapy fails to confer additional survival 
benefit, it does reduce the requirements of 
both plasma infusion and plasma exchange. 
From the emerging novel therapeutic 
adjuvants, rituximab is a clear front-runner, 
with studies demonstrating the benefit of 
reducing the number and severity of relapses.
TTP associated with connective tissue was 
first documented in the scientific literature 
in 1961, in a case of SLE-associated TTP. 
Since then there have been just under 100 
reported cases of SLE-associated TTP, which 
still represents the most common CTD 
association with TTP. TTP complicates SLE 
in only 0.7% of all SLE cases, and usually 
occurs in a patient with an established 
diagnosis of SLE.[6] In contrast to the SLE, 
the association of MCTD and TTP has only 
been represented in the literature by 15 case 
reports. There have been no previous reports 
of TTP complicating undifferentiated CTD. 
Although an indistinct clinical entity, 
undifferentiated CTD has been recognised 
as an important diagnosis in a patient with 
symptoms and signs of a CTD that do 
not fulfil the criteria for one of the more 
established connective tissue diagnoses.[7] 
In a prospective observational study, nearly 
70% of patients with a baseline diagnosis 
of undifferentiated CTD maintained the 
same diagnosis after 10 years, making a 
clear case for the disease’s recognition as 
an independent entity.[8] The majority of 
the remaining patients went on to fulfil the 
criteria for SLE over the 10 years of follow-up, 
suggesting that for this group of patients the 
diagnosis of undifferentiated CTD 10 years 
prior represented the evolution of early 
SLE into a clinically recognisable form. The 
underlying pathophysiological basis for TTP 
occurring in these CTDs is believed to be the 
presence of antibodies against ADAMTS13, 
complement activity against ADAMTS13 
and immune-mediated endothelial injury. [9] 
It is important to identify the features of 
TTP in the presence of CTD, as mortality 
approximates 100% if appropriate treatment 
is not initiated promptly.[10] Haemolytic 
anaemia, thrombocytopenia, fever, neuro-
logical features and renal dysfunction may 
all be erroneously attributed to a CTD 
flare, especially in the case of SLE where a 
lupus flare may present in this exact way. 
Important distinguishing features that may 
assist in diagnosing TTP in this context 
include the presence of schistocytes on 
peripheral smear, a negative Coombs test, 
normal complement levels, and a low level 
of ADAMTS13 activity.[6] In contrast, the 
absence of schistocytes, a positive Coombs 
test, low complement levels, and a normal 
level of ADAMTS13 activity suggest a CTD-
mediated haemolytic process rather than 
TTP. When the diagnosis of TTP is made 
in the presence of a CTD, treatment must 
include ongoing treatment of the CTD 
usually along with the use of steroids and 
cytotoxic agents. In addition, however, 
early plasmapheresis is essential to reduce 
mortality.[6,11,12] Where plasmapheresis is not 
available, plasma infusion is a recommended 
albeit inferior alternative. 
HIV-associated TTP represents a distinct 
clinical entity that is of great significance in 
regions of HIV hyperendemicity, where there 
are large numbers of untreated patients with 
severe immune deficiency. The aetiology of 
this entity is multifactorial, but led by the 
presence of a diffuse HIV vasculopathy. [13] 
The resultant ongoing endothelial cell 
infection and injury stimulate the release of 
unusually large VWF from damaged endo-
thelium. Importantly, absolute ADAMTS13 
deficiency is not strongly implicated in the 
pathogenesis of HIV-associated TTP.[14,15] 
However, the normal levels of ADAMTS13 
in these patients is overwhelmed by the 
profuse secretion of UL-VWF. A relative 
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deficiency of ADAMTS13 therefore occurs. This diffuse vasculopathy 
of HIV, and the resulting overwhelming of ADAMTS13 by UL-VWF 
secretion, characterises the occurrence of TTP in patients with 
advanced or untreated HIV. In these patients, there is emerging 
evidence that plasma infusion is non-inferior to plasma exchange, as 
the relative ADAMTS13 deficiency can be overcome by the infusion 
of plasma containing ADAMTS13. [16] As there is limited, if any, 
role of antibodies to ADAMTS13, there is no need for the plasma 
exchange, which ordinarily has the benefit of being able to remove 
these antibodies. However, where plasma infusion is used alone, 
close monitoring for clinical or haematological failure is imperative. 
Evidence for microangiopathic haemolysis should be sought by 
monitoring platelet count, haemoglobin, lactate dehydrogenase and 
schistocyte measurements on the peripheral smear.
In patients with treated HIV, in whom the HIV VL is suppressed and 
cellular immunity has been restored, the occurrence of TTP is more 
likely to be due to the pathogenic mechanisms outlined for classic or 
idiopathic TTP, where the disease is led by antibodies to ADAMTS13 
and therefore an absolute deficiency in ADAMTS13. [14,17- 19] In this 
group of patients with HIV, plasma exchange remains superior to 
plasma infusion. This is an important consideration, especially in 
settings where plasma exchange is a precious resource, and there 
is an inclination towards plasma infusion as the primary treatment 
modality for all HIV-positive patients, irrespective of their clinical, 
immunological or virological status. As greater numbers of patients 
with HIV become treated, the likelihood of the incident TTP being 
due to a diffuse HIV vasculopathy will be reduced. There must 
therefore be a similar paradigm shift in the determination of the 
primary treatment modality, with a lower threshold to offer plasma 
exchange. 
In our case, the patient had a background history of HIV and 
CTD. It was crucial to distinguish between the possible causes of 
haemolytic anaemia in the presence thrombocytopenia, neurological 
impairment and renal impairment. The possibility of a CTD flare was 
considered alongside the possibilities of a CTD-associated TTP or 
HIV-associated TTP; a distinction being important as each possibility 
required a unique treatment strategy. The diagnosis of TTP was 
distinguished from haemolytic anaemia related to her CTD by means 
of the profuse presence of schistocytes on peripheral smear, normal 
complement levels and negative Coombs test. The HIV VL was 
suppressed and there was clinical and immunological improvement 
on ART. An initial trial of plasma infusion without plasma exchange 
was attempted as the literature supported this approach for HIV-
associated TTP, and it has become common practice in our resource-
limited setting for HIV-associated TTP to be treated with a trial of 
plasma infusion alone before referral to central facilities with plasma 
exchange capabilities. Following the failure of this approach with our 
patient, plasma exchange was initiated and disease remission was 
achieved. 
TTP in the presence of HIV and CTD presents challenging diagnostic 
and therapeutic dilemmas. A CTD flare can look similar to TTP, but 
even once a diagnosis of TTP is arrived at, the treatment strategy 
must be tailored according to the most likely underlying pathological 
mechanism of the TTP. In resource-limited settings, where HIV-
associated TTP is more likely to be treated with a trial of plasma 
infusion alone, close monitoring for therapeutic failure must be 
performed so that appropriate escalation of therapy to plasma 
exchange can be initiated. A high index of clinical suspicion is 
necessary to make the diagnosis of idiopathic TTP in the presence of 
comorbidities, and early plasma exchange may be crucial to improve 
survival. 
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